Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker FDMT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | FDMT 4D Molecular Therapeutics, Inc. | State Street Corporation | 2.47M | 4.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 5.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Rajeev Shah | 5.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Peter Kolchinsky | 5.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | RA Capital Management, L.P. | 5.11M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Mark N. Lampert | 5.35M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Inc/Il | 5.35M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Partners L P/Il | 5.35M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF GP Holdings LLC | 5.00M | 9.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Partners OS Ltd. | 289,025 | 0.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP | 289,025 | 0.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF II GP LLC | 1.09M | 2.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Biotechnology Value Fund II LP | 1.09M | 2.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF I GP LLC | 3.91M | 7.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Biotechnology Value Fund L P | 3.91M | 7.3% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G | FDMT 4D Molecular Therapeutics, Inc. | State Street Corporation | 2.71M | 5.3% | SCHEDULE 13G ↗ |
| Apr 7, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Janus Henderson Group PLC | 5.25M | 10.3% | SCHEDULE 13G/A ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Novo Holdings A/S | 3.65M | 6.4% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 5.71M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Rajeev Shah | 5.71M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Peter Kolchinsky | 5.71M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | RA Capital Management, L.P. | 5.71M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | FDMT 4D Molecular Therapeutics, Inc. | Janus Henderson Group PLC | 4.64M | 8.1% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Mark N. Lampert | 5.85M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Inc/Il | 5.85M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Partners L P/Il | 5.85M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF GP Holdings LLC | 5.39M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Partners OS Ltd. | 378,475 | 0.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP | 378,475 | 0.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF II GP LLC | 1.80M | 3.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Biotechnology Value Fund II LP | 1.80M | 3.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF I GP LLC | 3.58M | 6.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Biotechnology Value Fund L P | 3.58M | 6.1% | SCHEDULE 13G/A ↗ |
| Feb 9, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Goldman Sachs & Co. LLC | 4.29M | 7.5% | SCHEDULE 13G/A ↗ |
| Feb 9, 2026 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | The Goldman Sachs Group, Inc. | 4.29M | 7.5% | SCHEDULE 13G/A ↗ |
| Oct 20, 2025 | SCHEDULE 13G | FDMT 4D Molecular Therapeutics, Inc. | Novo Holdings A/S | 3.17M | 6.8% | SCHEDULE 13G ↗ |
| Oct 17, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BlackRock, Inc. | 3.06M | 6.6% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Bong Y Koh | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Nimish Shah | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | VHCP Management EG, LLC | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | VHCP Management III, LLC | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | VHCP Co-Investment Holdings III, LLC | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 677,600 | 1.5% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | Mark N. Lampert | 4.63M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Inc/Il | 4.63M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Partners L P/Il | 4.63M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF GP Holdings LLC | 4.23M | 9.1% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | FDMT 4D Molecular Therapeutics, Inc. | BVF Partners OS Ltd. | 299,876 | 0.6% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances